Core Insights - Masivo Silver Corp. has intersected visible sulfide mineralization in holes No.2, No.3, and No.4 at the Boston Mine, indicating potential for high-grade gold, silver, and copper deposits [1][2] - The company is currently drilling Hole No.5 and has sent the core samples from holes No.2, No.3, and No.4 to an independent lab for assaying, with results expected in the coming weeks [2] Drilling Details - Hole No.2 was drilled to a depth of 456.05 feet - Hole No.3 reached a depth of 328 feet - Hole No.4 was drilled to a depth of 400 feet [2] Management Commentary - David Coburn, President & CEO, expressed excitement about the visible sulfide mineralization found in the cores of holes No.2, No.3, and No.4, and is looking forward to the assay results [2]

Group 1 - Masivo Silver Corp. has commenced drilling Hole BM-24-03 at the Boston Mine, targeting the down dip extension of high-grade ore [1] - The drill core from Hole BM-24-02 has been sent to a certified lab for analysis, with results expected in six weeks [2] - Hole No.2 exhibited continuous visible high mineralization, allowing the company to extend the hole depth by 100 feet beyond the expected depth [2]

908 Devices Inc. (MASS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.88%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced a loss of $0.33, delivering a surprise of 10.81%. Over the last four quarters, the company has surpas ...

Company Overview - 908 Devices Inc. (MASS) is expected to report a quarterly loss of $0.34 per share, reflecting a year-over-year decline of 17.2% [5] - Revenues are anticipated to be $13.69 million, which represents a 13.2% increase from the same quarter last year [6] Earnings Estimates and Trends - The consensus EPS estimate has been revised 2.74% lower over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [7] - The Most Accurate Estimate for 908 Devices is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.94% [13] Historical Performance - In the last reported quarter, 908 Devices was expected to post a loss of $0.37 per share but actually reported a loss of $0.33, achieving a surprise of +10.81% [16] - The company has beaten consensus EPS estimates in each of the last four quarters [17] Industry Context - In the Zacks Medical - Instruments industry, Teleflex (TFX) is expected to report earnings of $3.33 per share for the quarter ended June 2024, indicating a year-over-year change of -2.4% [21] - Teleflex's revenue is projected to be $763.39 million, up 2.7% from the previous year [21] - The consensus EPS estimate for Teleflex has remained unchanged over the last 30 days, but a lower Most Accurate Estimate has resulted in an Earnings ESP of -0.66% [22]

. . July 16, 2024 3:08 PM EDT | Source: Masivo Silver Corp. "Hole No.2 has shown very positive results, we are very pleased to have completed this hole after our technical team agreed to continue drilling the hole 100 feet beyond the expected depth thanks to the continuous visible high mineralization present on our drill core, this is what allowed us to extend the target depth 3 times, we are very excited to send our core to the lab for assaying," commented David Coburn, President & CEO. Nevada Drill Progra ...

908 Devices Inc. (MASS) closed the last trading session at $6.56, gaining 13.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.33 indicates a 133.7% upside potential. The average comprises three short-term price targets ranging from a low of $14 to a high of $17, with a standard deviation of $1.53. While the lowest estimate indicates an increase of 113.4% from the current pric ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Condensed Consolidated Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements for 908 Devices Inc. for the period ended March 31, 2024 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2024, total assets decreased to **$189.8 million** from **$203.0 million** at year-end 2023, primarily due to reduced cash and cash equivalents Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $104,599 | $121,041 | | Total current assets | $161,868 | $173,790 | | Total assets | $189,791 | $202,981 | | **Liabilities & Equity** | | | | Total current liabilities | $19,330 | $22,549 | | Total liabilities | $32,898 | $37,490 | | Total stockholders' equity | $156,893 | $165,491 | | Total liabilities and stockholders' equity | $189,791 | $202,981 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q1 2024, total revenue increased to **$10.0 million**, and net loss improved to **$10.9 million** from **$12.5 million** in Q1 2023 Q1 2024 vs Q1 2023 Statement of Operations (in thousands, except per share data) | Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Total revenue | $9,991 | $9,487 | | Gross profit | $5,003 | $4,384 | | Loss from operations | $(12,688) | $(13,017) | | Net loss | $(10,917) | $(12,532) | | Net loss per share (Basic and diluted) | $(0.33) | $(0.39) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2024, net cash used in operating activities improved to **$9.4 million**, resulting in a **$16.4 million** net decrease in cash and equivalents Q1 2024 vs Q1 2023 Cash Flow Summary (in thousands) | Activity | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | $(9,357) | $(10,647) | | Net cash used in investing activities | $(5,780) | $(1,185) | | Net cash used in financing activities | $(1,295) | $(15,381) | | **Net decrease in cash, cash equivalents and restricted cash** | **$(16,442)** | **$(27,208)** | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies, revenue disaggregation, and significant subsequent events, including the acquisition of RedWave Technology - The company is a commercial-stage technology firm providing handheld and desktop devices for chemical and biochemical analysis in markets like life sciences, bioprocessing, and forensics[22](index=22&type=chunk) Revenue by Stream (in thousands) | Revenue Stream | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | Device sales revenue | $5,452 | $5,083 | | Recurring revenue | $4,539 | $4,179 | | **Total product and service revenue** | **$9,991** | **$9,262** | | Contract revenue | $— | $225 | | **Total revenue** | **$9,991** | **$9,487** | - On April 29, 2024, the company acquired RedWave Technology for an initial payment of **$45.0 million** in cash and **1,497,171 shares** of common stock, with a potential earnout of up to **4,000,000 additional shares** based on revenue targets[113](index=113&type=chunk)[114](index=114&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=26&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2024 financial performance, highlighting a **5%** revenue increase to **$10.0 million** and sufficient liquidity of **$134.2 million** - The company develops and sells purpose-built handheld and desktop mass spectrometry devices for point-of-need chemical and biochemical analysis, serving markets such as life sciences, bioprocessing, and forensics[121](index=121&type=chunk) Product Placements (Units) | Period | Handheld | Desktop | | :--- | :--- | :--- | | **Q1 2024** | 53 | 8 | | **Q1 2023** | 62 | 16 | Cumulative Product Placements (Units) | As of | Handheld | Desktop | | :--- | :--- | :--- | | **March 31, 2024** | 2,475 | 439 | | **March 31, 2023** | 2,082 | 386 | - Total revenue for Q1 2024 increased by **$0.5 million (5%)** to **$10.0 million** compared to Q1 2023, driven by a **$0.2 million** increase in product revenue and a **$0.5 million** increase in service revenue, offset by a **$0.2 million** decrease in contract revenue[174](index=174&type=chunk)[175](index=175&type=chunk)[178](index=178&type=chunk) - The company believes its existing cash, cash equivalents, and marketable securities of **$134.2 million** as of March 31, 2024, are sufficient to fund operations for at least the next twelve months[191](index=191&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=40&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, the company is exempt from providing market risk disclosures - As a smaller reporting company, 908 Devices Inc. is exempt from providing quantitative and qualitative disclosures about market risk[215](index=215&type=chunk) [Controls and Procedures](index=40&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective, with no material changes in internal control over financial reporting - Based on an evaluation as of the end of the quarter, the principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective at a reasonable assurance level[216](index=216&type=chunk) - No changes in internal control over financial reporting occurred during the most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[217](index=217&type=chunk) [PART II. OTHER INFORMATION](index=41&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=41&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings - The company is not currently party to any material legal proceedings[219](index=219&type=chunk) [Risk Factors](index=41&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the company's risk factors were reported from the 2023 Form 10-K - There have been no material changes to the company's risk factors from those discussed in the 2023 Form 10-K[220](index=220&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=41&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities or use of proceeds were reported during the period - None[221](index=221&type=chunk) [Defaults Upon Senior Securities](index=41&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported - None[222](index=222&type=chunk) [Mine Safety Disclosures](index=41&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None[223](index=223&type=chunk) [Other Information](index=41&type=section&id=Item%205.%20Other%20Information) No Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were adopted or terminated by directors or executive officers - No directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2024[224](index=224&type=chunk) [Exhibits](index=42&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including CEO and CFO certifications and Inline XBRL data List of Exhibits | Exhibit | Description | | :--- | :--- | | 31.1 | CEO Certification (Sarbanes-Oxley Section 302) | | 31.2 | CFO Certification (Sarbanes-Oxley Section 302) | | 32.1 | CEO Certification (Sarbanes-Oxley Section 906) | | 32.2 | CFO Certification (Sarbanes-Oxley Section 906) | | 101 | Inline XBRL Documents | | 104 | Cover Page Data File |

908 Devices Inc. (MASS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.81%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.23, delivering a surprise of 14.81%.Over the last four quarters, the company has surpass ...

Exhibit 99.1 908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook First quarter 2024 product and service revenue increased 8% compared to prior year, driven by a 20% increase in handheld revenue Acquired RedWave Technology, expanding forensics product portfolio for point-of-need applications BOSTON – April 30, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial res ...

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the latest in international adoption of the MX908 for trace detection and identification of priority drugs and chemical threats. DrugDetect EU and NATO Support and Procurement Agency (NSPA) have both entered into new contracts to deploy the MX908, a handheld high-pressure mass spectrometry (HPMS) device. The MX908 will be used in a variety of sett ...